Category

• Pipeline2
• Business1
• Research1

Organizations

• Bausch + Lomb61
• Eyes On Eyecare41
• Alcon, Inc.38
• American Optometric Association34
• Harrow26
• Glaukos25
• Aldeyra Therapeutics20
• Regeneron19
• American Academy Of Ophthalmology18
• Coopervision18

Tags

• Glaucoma4
• Iols2
• Finance2
• Technology2
• Ascrs1
• Ocular Hypertension1
• Cataract Surgery1
• Clinical Trials1
• Finances1
• Financial1

• Organizations: SpyGlass Pharma, Inc✕

Clear all

Pipeline

SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform

Financing to support upcoming phase 3 trials on the company’s long-term delivery system of bimatoprost for glaucoma and OHT treatment.

Research

SpyGlass Pharma reports positive 18-month data on glaucoma sustained delivery system

Presented at ASCRS, new findings show promising visual outcomes and IOP lowering following sustained-release delivery of bimatoprost.

Business

SpyGlass Pharma secures $90M in financing for chronic ophthalmic disease drug delivery platform

First-of-its-kind controlled-release platform is designed to significantly lower IOP.

Pipeline

SpyGlass Pharma releases 6-month data from first-in-human trial for glaucoma

Breakthrough drug delivery platform demonstrates significant IOP lowering.